about
Yeast mating for combinatorial Fab library generation and surface displayYeast display of antibody fragments: a discovery and characterization platform.Moieties in an RNA promoter specifically recognized by a viral RNA-dependent RNA polymeraseProduction, purification, and characterization of human scFv antibodies expressed in Saccharomyces cerevisiae, Pichia pastoris, and Escherichia coli.Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A.Affinity maturation of tacrolimus antibody for improved immunoassay performance.Antibody affinity optimization using yeast cell surface display.Sequence-specific recognition of a subgenomic RNA promoter by a viral RNA polymeraseA paracrine signal mediates the cell transformation response to low dose gamma radiation in JB6 cells.Novel sandwich immunoassays for the measurement of total and active FGF21.Development of a novel clinical biomarker assay to detect and quantify aggrecanase-generated aggrecan fragments in human synovial fluid, serum and urine.Determination of cathepsin S abundance and activity in human plasma and implications for clinical investigation.A quantitative tool to distinguish isobaric leucine and isoleucine residues for mass spectrometry-based de novo monoclonal antibody sequencing.Directed evolution for the development of conformation-specific affinity reagents using yeast display.Dual-monoclonal, sandwich immunoassay specific for glucose-dependent insulinotropic peptide1-42, the active form of the incretin hormone.A novel, high-sensitivity and drug-tolerant sandwich immunoassay for the quantitative measurement of circulating proteins.Using an in vivo phagemid system to identify non-compatible loxP sequencesUsing an in vivo phagemid system to identify non-compatible loxP sequencesA novel high-sensitivity electrochemiluminescence (ECL) sandwich immunoassay for the specific quantitative measurement of plasma glucagonInvestigation of pre-existing reactivity to biotherapeutics can uncover potential immunogenic epitopes and predict immunogenicity riskPost-hoc assessment of the immunogenicity of three antibodies reveals distinct immune stimulatory mechanisms
P50
Q28257249-E764CDA3-3168-4220-8211-DA783ECFD07DQ31096007-5A75D369-0666-4E72-A753-E8229B71BB0FQ32015360-1CCE26F9-1329-4524-B6E2-A088B6787AA4Q33216783-21499480-B94B-480B-B3F8-40BB727E3F7DQ33218388-20FC2F3F-9D25-46D4-A2E6-0A5331071E54Q33327646-ACEBABF9-9DE1-4423-864C-95A1E2E7B861Q33401627-C593B17F-C942-451E-847E-0D7AE9790B1AQ36590392-C6441D80-598D-4938-BEDD-2D00CEEB8ABFQ40440777-4982F662-89DF-45A6-A2DD-F8DE559C3CB7Q41656537-2E6C0741-EA47-4B0A-8C03-FD48BB00F41BQ42969297-5F1D07E7-4F5B-4114-BF39-DCC890975F93Q43858080-741ECA96-1905-44A7-80A9-371FF212C8A9Q44464970-07890580-6A08-4989-A031-2D2510E68DD6Q46722215-DB24C44C-6B3C-4B88-99E3-FD0F385662F5Q51374647-AD3A65AC-2DA6-4291-9CBB-856600E03090Q53671100-FD693409-828A-4988-93B8-E2D1ED0AC102Q74063110-63378345-981F-42AA-B311-011E19506F26Q74567366-C5806B9A-792E-45DA-8E3D-2DEB65ABD21DQ84788259-BEF8B442-497A-4EA7-93D6-B63815FB4F8EQ92110303-4AD0076F-7CD2-4439-A173-9AA95261C230Q94546300-2C375CB0-FD34-4457-B6CC-8897DDC01E66
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Robert W. Siegel
@ast
Robert W. Siegel
@en
Robert W. Siegel
@es
Robert W. Siegel
@nl
Robert W. Siegel
@sl
type
label
Robert W. Siegel
@ast
Robert W. Siegel
@en
Robert W. Siegel
@es
Robert W. Siegel
@nl
Robert W. Siegel
@sl
prefLabel
Robert W. Siegel
@ast
Robert W. Siegel
@en
Robert W. Siegel
@es
Robert W. Siegel
@nl
Robert W. Siegel
@sl
P106
P1153
7401836230
P21
P31
P496
0000-0002-0833-5580